科学研究 - The Left Main and Coronary Artery Bifurcation Lesion Summit (CBS)

文章摘要

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial
Outcome of Applying the ESC 0/1-hour Algorithm in Patients With Suspected Myocardial Infarction
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up
Canadian Multicenter Chronic Total Occlusion Registry: Ten-Year Follow-Up Results of Chronic Total Occlusion Revascularization
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
Prevalence, Presentation and Treatment of 'Balloon Undilatable' Chronic Total Occlusions: Insights from a Multicenter US Registry
Long-Term Prognostic Implications of Previous Silent Myocardial Infarction in Patients Presenting With Acute Myocardial Infarction
Drug-eluting balloons in coronary interventions: the quiet revolution?
Guiding Principles for Chronic Total Occlusion Percutaneous Coronary Intervention
Efficacy and Safety of Stents in ST-Segment Elevation Myocardial Infarction

Clinical Trial

2020 Nov 11.

JOURNAL：Circulation.

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial

SD Anker, J Butler, EMPEROR-Reduced Trial Committees and Investigators et al.

16423

Keywords: cardiorenal outcomes; empagliflozin

Full Text PDF